Paolo Ambrosini

Milan, Italy

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 23 publications

Alectinib and gastrointestinal perforation in ALK-rearranged non-small cell lung cancer: A case series.

Alectinib and gastrointestinal perforation in ALK-rearranged non-small cell lung cancer: A case series.

Journal: Tumori

Published: June 04, 2026

Network analysis predicts pembrolizumab response in advanced NSCLC with PD-L1 < 50.

Network analysis predicts pembrolizumab response in advanced NSCLC with PD-L1 < 50.

Journal: Cancer cell international

Published: November 06, 2025

Clinician expertise and prompt engineering enhance cancer information extraction in electronic health records by small language models.

Clinician expertise and prompt engineering enhance cancer information extraction in electronic health records by small language models.

Journal: Communications medicine

Published: October 24, 2025

Locoregional therapies in advanced and recurrent pleural mesothelioma: A systematic review.

Locoregional therapies in advanced and recurrent pleural mesothelioma: A systematic review.

Journal: Lung cancer (Amsterdam, Netherlands)

Published: October 09, 2025

Towards a new approach in pleural mesothelioma: Perioperative immunotherapy and its implications.

Towards a new approach in pleural mesothelioma: Perioperative immunotherapy and its implications.

Journal: Critical reviews in oncology/hematology

Published: June 23, 2025

Real-World Outcomes of Molecular Tumor Board Treatment Recommendations.

Real-World Outcomes of Molecular Tumor Board Treatment Recommendations.

Journal: JCO precision oncology

Published: June 11, 2025

Benchmarking progression-free survival ratio as primary endpoint in precision oncology clinical trials.

Benchmarking progression-free survival ratio as primary endpoint in precision oncology clinical trials.

Journal: NPJ precision oncology

Published: May 14, 2025

Refining High-Risk EGFR-Mutant Lung Cancer Patients: The Role of Adjusted Variant Allele Frequency in First-Line Osimertinib Therapy.

Refining High-Risk EGFR-Mutant Lung Cancer Patients: The Role of Adjusted Variant Allele Frequency in First-Line Osimertinib Therapy.

Journal: Clinical lung cancer

Published: April 14, 2025

Immune-checkpoint targeting drug conjugates: a novel class of promising therapeutic agents for cancer treatment.

Immune-checkpoint targeting drug conjugates: a novel class of promising therapeutic agents for cancer treatment.

Journal: NPJ precision oncology

Published: April 14, 2025

APOLLO11: a bio-data-driven model for clinical and translational research in lung cancer.

APOLLO11: a bio-data-driven model for clinical and translational research in lung cancer.

Journal: NPJ precision oncology

Published: April 03, 2025

Lenvatinib in advanced thyroid, salivary gland, endometrial, and hepatocellular carcinomas: a real-world study on treatment duration and toxicity management.

Lenvatinib in advanced thyroid, salivary gland, endometrial, and hepatocellular carcinomas: a real-world study on treatment duration and toxicity management.

Journal: Therapeutic advances in medical oncology

Published: March 11, 2025

Hot topics in genitourinary cancers: A multidisciplinary discussion on state-of-the-art and latest developments among international experts and patient advocacy.

Hot topics in genitourinary cancers: A multidisciplinary discussion on state-of-the-art and latest developments among international experts and patient advocacy.

Journal: Tumori

Published: October 07, 2024

Showing 1-12 of 23

Last Updated: 09/26/2026